Dermatologic events associated with the anti-CCR4 antibody mogamulizumab: Characterization and management Review


Authors: Musiek, A. C. M.; Rieger, K. E.; Bagot, M.; Choi, J. N.; Fisher, D. C.; Guitart, J.; Haun, P. L.; Horwitz, S. M.; Huen, A. O. L.; Kwong, B. Y.; Lacouture, M. E.; Noor, S. J.; Rook, A. H.; Seminario-Vidal, L.; Vermeer, M. H.; Kim, Y. H.
Review Title: Dermatologic events associated with the anti-CCR4 antibody mogamulizumab: Characterization and management
Abstract: The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival and overall response rate compared with vorinostat in adults with relapsed/refractory mycosis fungoides (MF) and Sezary syndrome (SS). One of the most common adverse events seen with mogamulizumab in MF/SS patients is rash. Because of the protean nature of MF/SS and the variable clinical and histopathological features of mogamulizumab-associated rash, healthcare providers may have difficulty distinguishing rash from disease, and may not be aware of appropriate treatment strategies for this generally manageable adverse event. The objective of this report was to combine results from published literature with experiences and recommendations from multiple investigators and institutions into clinical best practice recommendations to assist healthcare providers in identifying and managing mogamulizumab-associated rash. Optimal management, which includes biopsy confirmation and steroid treatment, requires a multidisciplinary approach among oncology, dermatology, and pathology practitioners.
Keywords: leukemia; rash; skin; cutaneous t-cell lymphoma; t-cell lymphoma; mycosis fungoides; consortium; sezary syndrome; eruption; sezary-syndrome; mycosis-fungoides; ccr4 expression; mogamulizumab; kw-0761
Journal Title: Dermatology and Therapy
Volume: 12
Issue: 1
ISSN: 2193-8210
Publisher: Adis Int Ltd  
Date Published: 2022-01-01
Start Page: 29
End Page: 40
Language: English
ACCESSION: WOS:000721645200001
DOI: 10.1007/s13555-021-00624-7
PROVIDER: wos
PMCID: PMC8776934
PUBMED: 34816383
Notes: Review -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mario E Lacouture
    457 Lacouture
  2. Steven M Horwitz
    645 Horwitz
  3. Sarah J Noor
    41 Noor